The shell of the SN Operator is constructed of optical-grade polycarbonate and features flaps to keep dust and debris at bay. Epilogue also baked in overcurrent ...

An update from CSPC Pharmaceutical Group ( (HK:1093)) is now available. CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials ...

CSPC Pharmaceutical Group ( (HK:1093)) has provided an announcement. CSPC Pharmaceutical Group Limited has disclosed an updated list of its board of directors, confirming a large slate of executive ...

UK supermajor Shell has announced it is pulling out of the initial phase of the multibillion-dollar Argentina LNG project, a year after announcing its participation in the project. Shell and Argentina ...

In business as in medicine, a remedy can take time to kick in. This is the challenge for Chinese drug giant CSPC Pharmaceutical Group Ltd. (1093.HK), which is trying to transform itself from being a ...

Madrigal Pharmaceuticals Inc. and CSPC Pharmaceutical Group Ltd. have entered into an exclusive global license agreement for CSPC’s SYH-2086, a preclinical oral small-molecule glucagon-like peptide-1 ...

Shell rebuffed a Wall Street Journal report that said the oil giant was in early talks to take over rival company BP. “This is further market speculation. No talks are taking place,” the company said ...

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion. The ...

AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs. The R ...

AstraZeneca has returned to recent licensing partner CSPC Pharmaceutical with $110 million in upfront cash to start work on finding new oral drugs for a range of chronic diseases. The Friday morning ...

CSPC Pharma was already on track for a tough earnings season after its nine-month profits fell 15.9% Another blow was the sudden departure of the firm's head of innovative drug research, Liu Yongjun, ...